Nurix Therapeutics shares are trading higher after Morgan Stanley maintained an Equal-Weight rating on the stock and raised its price target from $11 to $12.
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley has maintained an Equal-Weight rating on Nurix Therapeutics and raised its price target from $11 to $12. This has resulted in Nurix Therapeutics' shares trading higher.
July 17, 2023 | 2:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Nurix Therapeutics and raised its price target, leading to a rise in the company's share price.
The news of Morgan Stanley maintaining an Equal-Weight rating and raising the price target for Nurix Therapeutics has a direct impact on the company's stock. This positive outlook from a major financial institution can boost investor confidence, leading to an increase in the stock's demand and subsequently its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100